Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17130887 | DIFFERENTIATION OF SIGNALS FOR TARGET NUCLEIC ACID SEQUENCES | December 2020 | September 2023 | Allow | 33 | 1 | 0 | No | No |
| 17087300 | SYSTEMS AND METHODS FOR ANALYZING SEQUENCE DATA | November 2020 | March 2023 | Allow | 29 | 1 | 0 | No | No |
| 16920356 | ELECTRIC REACTION MEASURING APPARATUS, ELECTRIC REACTION PROCESSING METHOD, AND RECORDING MEDIUM | July 2020 | December 2023 | Allow | 42 | 1 | 0 | Yes | No |
| 16918489 | Systems, Methods and Devices for Achieving Glycemic Balance | July 2020 | July 2023 | Allow | 37 | 1 | 0 | No | No |
| 16881928 | SYSTEMS AND METHODS FOR DETERMINING WHETHER A SUBJECT HAS A CANCER CONDITION USING TRANSFER LEARNING | May 2020 | August 2023 | Allow | 39 | 1 | 1 | Yes | No |
| 16863403 | CROSS-VARIANT POLYGENIC PREDICTIVE DATA ANALYSIS | April 2020 | December 2023 | Allow | 44 | 1 | 1 | No | No |
| 16841556 | ADJUSTMENT OF TOOTH POSITION IN A VIRTUAL DENTAL MODEL | April 2020 | February 2023 | Allow | 34 | 1 | 0 | No | No |
| 16833172 | Bioinformatics Systems, Apparatuses, and Methods Executed on an Integrated Circuit Processing Platform | March 2020 | July 2023 | Allow | 39 | 2 | 0 | No | No |
| 16817161 | SYSTEMS, DEVICES, AND METHODS FOR ALLEVIATING GLUCOTOXICITY AND RESTORING PANCREATIC BETA-CELL FUNCTION IN ADVANCED DIABETES MELLITUS | March 2020 | March 2023 | Allow | 36 | 1 | 0 | No | No |
| 16816918 | SYSTEMS AND METHODS FOR ENRICHING FOR CANCER-DERIVED FRAGMENTS USING FRAGMENT SIZE | March 2020 | October 2023 | Allow | 44 | 2 | 1 | Yes | No |
| 16815475 | Methods of Assessing Cellular Breast Samples and Compositions for Use in Practicing the Same | March 2020 | January 2024 | Allow | 47 | 1 | 1 | No | No |
| 16773804 | SYSTEM, APPARATUS, METHOD, AND GRAPHICAL USER INTERFACE FOR SCREENING | January 2020 | March 2023 | Allow | 37 | 1 | 0 | No | No |
| 16633279 | METHODS FOR PREPARING OLIGONUCLEOTIDES FOR DETECTING TARGET NUCLEIC ACID SEQUENCES WITH A MAXIMUM COVERAGE | January 2020 | September 2023 | Allow | 44 | 2 | 0 | Yes | No |
| 16739617 | SYSTEMS AND METHODS FOR DETECTING GLUCOSE LEVEL DATA PATTERNS | January 2020 | March 2023 | Allow | 38 | 2 | 0 | Yes | No |
| 16704847 | PREDICTING RESPIRATORY DISTRESS | December 2019 | August 2023 | Allow | 44 | 1 | 0 | Yes | No |
| 16704885 | INFUSION MANAGEMENT PLATFORM WITH INFUSION DATA GROUPING LOGIC | December 2019 | September 2022 | Allow | 34 | 1 | 0 | No | No |
| 16696783 | BLOOD CONDITION ANALYZING DEVICE, BLOOD CONDITION ANALYZING SYSTEM, AND BLOOD CONDITION ANALYZING PROGRAM | November 2019 | December 2022 | Allow | 37 | 1 | 0 | No | No |
| 16694789 | METHOD OF PREDICTING A PERFORMANCE CHARACTERISTIC OF A PLANT OR YEAST HYDROLYSATE AND ITS USE | November 2019 | January 2023 | Allow | 37 | 1 | 0 | No | No |
| 16685455 | DRUG COMPOUND IDENTIFICATION FOR TARGET TISSUE CELLS | November 2019 | January 2023 | Allow | 38 | 1 | 0 | Yes | No |
| 16658087 | METHODS AND SYSTEMS OF EVALUATING A RISK OF A GASTROINTESTINAL CANCER | October 2019 | January 2023 | Allow | 39 | 1 | 0 | No | No |
| 16566698 | ANALYSIS OF FRAGMENTATION PATTERNS OF CELL-FREE DNA | September 2019 | November 2022 | Allow | 38 | 1 | 0 | Yes | No |
| 16566695 | ANALYSIS OF FRAGMENTATION PATTERNS OF CELL-FREE DNA | September 2019 | September 2022 | Allow | 37 | 1 | 0 | Yes | No |
| 16566686 | ANALYSIS OF FRAGMENTATION PATTERNS OF CELL-FREE DNA | September 2019 | November 2022 | Allow | 38 | 1 | 0 | Yes | No |
| 16485714 | METHOD OF DIAGNOSING CANCER USING MITOCHONDRIAL DNA HETEROGENEITY | August 2019 | October 2022 | Abandon | 38 | 1 | 0 | No | No |
| 16429409 | DYNAMIC MEDICAL ECOSYSTEMS AND INTELLIGENCE MODELING | June 2019 | November 2023 | Abandon | 53 | 1 | 0 | No | No |
| 16413399 | DRUG EFFICACY PREDICTION FOR TREATMENT OF GENETIC DISEASE | May 2019 | January 2023 | Allow | 44 | 1 | 0 | Yes | No |
| 16404618 | METHOD AND SYSTEM FOR AUTOMATING CURATION OF GENETIC DATA | May 2019 | April 2023 | Abandon | 47 | 1 | 0 | No | No |
| 16343256 | LEVERAGING THE PRESENCE OR ABSENCE OF MIRNA ISOFORMS FOR RECOMMENDING THERAPY IN CANCER PATIENTS | April 2019 | September 2023 | Allow | 53 | 2 | 1 | No | No |
| 16288049 | MULTIMODAL MODELING SYSTEMS AND METHODS FOR PREDICTING AND MANAGING DEMENTIA RISK FOR INDIVIDUALS | February 2019 | January 2024 | Abandon | 58 | 1 | 1 | No | No |
| 16248084 | DETERMINING DRUG EFFECTIVENESS RANKING FOR A PATIENT USING MACHINE LEARNING | January 2019 | March 2023 | Allow | 50 | 1 | 0 | Yes | No |
| 16245249 | Method and systems for creating and screening patient metabolite profile to diagnose current medical condition, diagnose current treatment state and recommend new treatment regimen | January 2019 | July 2024 | Abandon | 60 | 2 | 1 | Yes | No |
| 16314261 | CORE CALIBRATION OF ANALYZERS | December 2018 | March 2023 | Allow | 51 | 1 | 0 | No | No |
| 16228840 | Method of Dosing a Patient with Multiple Drugs Using Adjusted Phenotypes of CYP450 Enzymes | December 2018 | February 2024 | Allow | 60 | 2 | 0 | No | No |
| 16221073 | ANALYTICS AND MACHINE LEARNING FRAMEWORK FOR ACTIONABLE INTELLIGENCE FROM CLINICAL AND OMICS DATA | December 2018 | August 2023 | Allow | 56 | 1 | 1 | No | No |
| 16307821 | CELL-FREE DNA METHYLATION PATTERNS FOR DISEASE AND CONDITION ANALYSIS | December 2018 | June 2022 | Allow | 43 | 2 | 1 | No | No |
| 16092396 | METHOD AND APPARATUS FOR PROVIDING A PHARMACOKINETIC DRUG DOSING REGIMENT | October 2018 | February 2023 | Allow | 52 | 2 | 0 | Yes | No |
| 16150137 | METHODS AND SYSTEMS FOR COMPUTER-GENERATED PREDICTIVE APPLICATION OF NEUROIMAGING AND GENE EXPRESSION MAPPING DATA | October 2018 | May 2023 | Allow | 56 | 1 | 1 | Yes | No |
| 16145722 | DETERMINATION OF MAPK-AP-1 PATHWAY ACTIVITY USING UNIQUE COMBINATION OF TARGET GENES | September 2018 | May 2023 | Allow | 56 | 1 | 1 | No | No |
| 16084941 | METHOD AND SYSTEM FOR MICROBIOME-DERIVED DIAGNOSTICS AND THERAPEUTICS INFECTIOUS DISEASE AND OTHER HEALTH CONDITIONS ASSOCIATED WITH ANTIBIOTIC USAGE | September 2018 | May 2023 | Allow | 56 | 1 | 1 | No | No |
| 16124702 | SYSTEMS AND METHODS FOR LEVERAGING RELATEDNESS IN GENOMIC DATA ANALYSIS | September 2018 | January 2022 | Allow | 41 | 1 | 0 | Yes | No |
| 16080421 | METHODS OF TREATING CANCER | August 2018 | March 2023 | Allow | 55 | 1 | 1 | Yes | No |
| 16071883 | METHOD OF DETECTING FETAL CHROMOSOMAL ANEUPLOIDY | July 2018 | May 2023 | Allow | 58 | 2 | 1 | Yes | No |
| 16037503 | CANCER DIAGNOSTIC APPARATUS AND CANCER DIAGNOSTIC SYSTEM USING THE SAME | July 2018 | September 2023 | Allow | 60 | 1 | 1 | No | No |
| 16062173 | SIGNAL EXTRACTION FOR A TARGET NUCLEIC ACID SEQUENCE | June 2018 | April 2022 | Allow | 46 | 1 | 1 | No | No |
| 15986617 | DELIVERING A CHEMICAL COMPOUND BASED ON A MEASURE OF TRUST DYNAMICS | May 2018 | September 2022 | Allow | 52 | 1 | 0 | Yes | No |
| 15772135 | PREDICTION OF ACUTE RESPIRATORY DISEASE SYNDROME (ARDS) BASED ON PATIENTS' PHYSIOLOGICAL RESPONSES | April 2018 | January 2024 | Abandon | 60 | 3 | 1 | No | No |
| 15918404 | Ketone Body Concentration Estimation Device, Method, and Computer-Readable Storage Medium | March 2018 | May 2023 | Allow | 60 | 2 | 1 | Yes | No |
| 15912584 | SYSTEM AND METHOD FOR CANCER DETECTION | March 2018 | March 2022 | Abandon | 48 | 1 | 1 | No | No |
| 15745468 | METHOD FOR EVALUATING PHYSICAL CONDITIONS, METHOD FOR PRESENTING INFORMATION, AND METHOD FOR SCREENING FOR SUBSTANCE CAPABLE OF IMPROVING OR PREVENTING PHYSICAL CONDITIONS | January 2018 | August 2023 | Allow | 60 | 3 | 1 | Yes | No |
| 15855294 | KEY-VALUE STORE THAT HARNESSES LIVE MICRO-ORGANISMS TO STORE AND RETRIEVE DIGITAL INFORMATION | December 2017 | May 2022 | Allow | 52 | 2 | 1 | No | No |
| 15727022 | METHODS AND SYSTEMS FOR DETERMINING PERSONALIZED THERAPIES | October 2017 | July 2022 | Allow | 58 | 2 | 1 | No | No |
| 15560056 | METABOLOMICS PROFILING OF CENTRAL NERVOUS SYSTEM INJURY | September 2017 | August 2022 | Allow | 58 | 3 | 0 | Yes | No |
| 15559719 | SYSTEMS AND METHODS OF FRAGMENT-CENTRIC TOPOGRAPHICAL MAPPING (FCTM) TO TARGET PROTEIN-PROTEIN INTERACTIONS | September 2017 | August 2022 | Allow | 59 | 1 | 1 | Yes | No |
| 15329016 | METHODS AND PROCESSES FOR NON-INVASIVE ASSESSMENT OF GENETIC VARIATIONS | January 2017 | May 2023 | Allow | 60 | 3 | 1 | No | No |
| 15294526 | METHOD AND SYSTEM FOR MICROBIOME-DERIVED DIAGNOSTICS AND THERAPEUTICS FOR CONDITIONS ASSOCIATED WITH MICROBIOME TAXONOMIC FEATURES | October 2016 | October 2019 | Abandon | 37 | 2 | 1 | Yes | No |
| 14941736 | Wearable sports monitoring equipment and method for characterizing sports performances or sportspersons | November 2015 | June 2023 | Allow | 60 | 6 | 0 | Yes | No |
| 14942592 | DIABETES ONSET AND PROGRESSION PREDICTION USING A COMPUTERIZED MODEL | November 2015 | November 2022 | Abandon | 60 | 6 | 1 | No | Yes |
| 14665658 | DIAGNOSTIC METHODS AND DEVICES FOR CONTROLLING ACUTE GLYCEMIA | March 2015 | April 2021 | Abandon | 60 | 7 | 0 | Yes | No |
| 13417119 | DIAGNOSING FETAL CHROMOSOMAL ANEUPLOIDY USING MASSIVELY PARALLEL GENOMIC SEQUENCING | March 2012 | November 2012 | Allow | 8 | 2 | 1 | Yes | No |
| 13070240 | DIAGNOSING FETAL CHROMOSOMAL ANEUPLOIDY USING MASSIVELY PARALLEL GENOMIC SEQUENCING | March 2011 | February 2024 | Allow | 60 | 1 | 2 | No | No |
| 13070251 | DIAGNOSING FETAL CHROMOSOMAL ANEUPLOIDY USING MASSIVELY PARALLEL GENOMIC SEQUENCING | March 2011 | April 2024 | Allow | 60 | 2 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner LIN, JERRY.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner LIN, JERRY works in Art Unit 1671 and has examined 61 patent applications in our dataset. With an allowance rate of 83.6%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 47 months.
Examiner LIN, JERRY's allowance rate of 83.6% places them in the 59% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by LIN, JERRY receive 1.66 office actions before reaching final disposition. This places the examiner in the 30% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by LIN, JERRY is 47 months. This places the examiner in the 10% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +9.5% benefit to allowance rate for applications examined by LIN, JERRY. This interview benefit is in the 41% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.
When applicants file an RCE with this examiner, 35.3% of applications are subsequently allowed. This success rate is in the 80% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 33.3% of cases where such amendments are filed. This entry rate is in the 50% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 0.0% of appeals filed. This is in the 0% percentile among all examiners. Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 100.0% are granted (fully or in part). This grant rate is in the 90% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 31.4% of allowed cases (in the 97% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.